Department of Stem Cell Transplantation and Cellular Therapy, University of Texas-MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Best Pract Res Clin Haematol. 2013 Sep;26(3):297-300. doi: 10.1016/j.beha.2013.10.011. Epub 2013 Oct 16.
Allogeneic hematopoietic transplantation, an effective treatment for acute myeloid leukemia (AML), was originally developed as a means of delivering high-dose myeloablative chemotherapy or radiation. The transplant itself allowed stem cells to restore normal hematopoiesis and immunity. Yet older people were denied this treatment because the myeloablative therapy has considerable toxicity. More recently, reduced-intensity conditioning has been used, allowing older or medically infirm patients to receive a transplant. This review explores the feasibility of transplant as a standard of care for older patients.
异基因造血干细胞移植是治疗急性髓细胞白血病（AML）的有效方法，最初是作为一种提供大剂量清髓性化疗或放疗的手段而发展起来的。移植本身使干细胞能够恢复正常的造血和免疫功能。然而，老年人被拒绝接受这种治疗，因为这种清髓性治疗有相当大的毒性。最近，采用了强度降低的预处理方案，使年龄较大或身体虚弱的患者能够接受移植。这篇综述探讨了将移植作为老年患者标准治疗的可行性。
